29770111|t|Chronic Caffeine Treatment Protects Against alpha-Synucleinopathy by Reestablishing Autophagy Activity in the Mouse Striatum.
29770111|a|Despite converging epidemiological evidence for the inverse relationship of regular caffeine consumption and risk of developing Parkinson's disease (PD) with animal studies demonstrating protective effect of caffeine in various neurotoxin models of PD, whether caffeine can protect against mutant alpha-synuclein (alpha-Syn) A53T-induced neurotoxicity in intact animals has not been examined. Here, we determined the effect of chronic caffeine treatment using the alpha-Syn fibril model of PD by intra-striatal injection of preformed A53T alpha-Syn fibrils. We demonstrated that chronic caffeine treatment blunted a cascade of pathological events leading to alpha-synucleinopathy, including pSer129alpha-Syn-rich aggregates, apoptotic neuronal cell death, microglia, and astroglia reactivation. Importantly, chronic caffeine treatment did not affect autophagy processes in the normal striatum, but selectively reversed alpha-Syn-induced defects in macroautophagy (by enhancing microtubule-associated protein 1 light chain 3, and reducing the receptor protein sequestosome 1, SQSTM1/p62) and chaperone-mediated autophagy (CMA, by enhancing LAMP2A). These findings support that caffeine-a strongly protective environment factor as suggested by epidemiological evidence-may represent a novel pharmacological therapy for PD by targeting autophagy pathway.
29770111	8	16	Caffeine	Chemical	MESH:D002110
29770111	44	65	alpha-Synucleinopathy	Disease	MESH:D000080874
29770111	110	115	Mouse	Species	10090
29770111	210	218	caffeine	Chemical	MESH:D002110
29770111	254	273	Parkinson's disease	Disease	MESH:D010300
29770111	275	277	PD	Disease	MESH:D010300
29770111	334	342	caffeine	Chemical	MESH:D002110
29770111	375	377	PD	Disease	MESH:D010300
29770111	387	395	caffeine	Chemical	MESH:D002110
29770111	423	438	alpha-synuclein	Gene	20617
29770111	440	449	alpha-Syn	Gene	20617
29770111	451	455	A53T	ProteinMutation	tmVar:p|SUB|A|53|T;HGVS:p.A53T;VariantGroup:0;OriginalGene:20617;CorrespondingGene:6622;RS#:104893877;CorrespondingSpecies:10090;CA#:257068
29770111	464	477	neurotoxicity	Disease	MESH:D020258
29770111	561	569	caffeine	Chemical	MESH:D002110
29770111	590	599	alpha-Syn	Gene	20617
29770111	616	618	PD	Disease	MESH:D010300
29770111	660	664	A53T	ProteinMutation	tmVar:p|SUB|A|53|T;HGVS:p.A53T;VariantGroup:0;OriginalGene:20617;CorrespondingGene:6622;RS#:104893877;CorrespondingSpecies:10090;CA#:257068
29770111	665	674	alpha-Syn	Gene	20617
29770111	713	721	caffeine	Chemical	MESH:D002110
29770111	784	805	alpha-synucleinopathy	Disease	MESH:D000080874
29770111	942	950	caffeine	Chemical	MESH:D002110
29770111	1045	1054	alpha-Syn	Gene	20617
29770111	1185	1199	sequestosome 1	Gene	18412
29770111	1201	1207	SQSTM1	Gene	18412
29770111	1208	1211	p62	Gene	18412
29770111	1265	1271	LAMP2A	Gene	16784
29770111	1302	1310	caffeine	Chemical	MESH:D002110
29770111	1443	1445	PD	Disease	MESH:D010300
29770111	Positive_Correlation	MESH:D002110	16784
29770111	Association	MESH:D010300	20617
29770111	Negative_Correlation	MESH:D002110	18412
29770111	Association	MESH:D020258	20617
29770111	Positive_Correlation	MESH:D020258	RS#:104893877;HGVS:p.A53T;CorrespondingGene:6622
29770111	Negative_Correlation	MESH:D002110	MESH:D000080874
29770111	Negative_Correlation	MESH:D002110	MESH:D010300
29770111	Association	18412	20617
29770111	Negative_Correlation	MESH:D002110	20617
29770111	Negative_Correlation	MESH:D002110	MESH:D020258
29770111	Association	MESH:D020258	6622

